Oral prifemilast, a PDE4B-selective inhibitor, led to PASI 75 attainment in up to 57.4% of those with psoriasis at week 16 vs 10.8% with placebo.
News|Articles|October 10, 2026
Fall Clinical 2026 First Half Recap: Psoriasis, Atopic Dermatitis, and More
Author(s)Tim Smith
Fact checked by: Chelsie Derman
Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.
Advertisement
Advertisement
The first half of the
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Final VALUE data show fewer drug changes with risankizumab vs other biologics over 37 months in patients with psoriasis and comorbid psoriatic arthritis.
This Q&A interview segment with Harrison Nguyen, MD, MBA, MPH, highlights key points made during his 2026 Fall Clinical Dermatology meeting sessions.
In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.
In this segment of her interview, Kimball discusses phase 2b tulisokibart data in hidradenitis suppurativa and the rationale for targeting TL1A.
Michael Wechsler, MD, discusses SWIFT/AGILE data showing 59% of patients in remission with depemokimab at year 1 maintained it at year 2.
Advertisement
Advertisement